SCHEMBL19684895

SCHEMBL19684895

CCCCOc1cc(Cl)cc2c1C(=O)NCCO2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP6 P51161 1/20 0.35
PDE4D Q08499 4/20 0.33
PDE4B Q07343 3/20 0.33
PDE4A P27815 3/20 0.33
PDE4C Q08493 2/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GLA P06280 1/20 0.33
ALPL P05186 1/20 0.32
KCNH2 Q12809 1/20 0.32
MAOB P27338 1/20 0.32
MAPK1 P28482 3/20 0.32
LMNA P02545 2/20 0.32
THRB P10828 2/20 0.32
TSHR P16473 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
TNF P01375 1/20 0.32
MAPT P10636 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19684745 0.86 CNR2 (0.35) FABP6PDE4DPDE4BPDE4APDE4C
SCHEMBL19684894 0.78 GRM5 (0.43) RAB9ASMN1; SMN2MAOBNPSR1KDM4E
SCHEMBL19679352 0.74 FABP6 (0.42) FABP6GLATSHRMAPTKDM4E
SCHEMBL19679353 0.71 FABP6 (0.42) FABP6GLAMAPTPDE3BPDE3A
SCHEMBL15525854 0.71 FABP6 (0.49) FABP6GLAMAPTKDM4EATM
SCHEMBL19684924 0.67 PARP10 (0.41) PDE4DPDE4BPDE4APDE4CSMN1; SMN2
SCHEMBL19667307 0.65 GRM5 (0.42) RAB9ASMN1; SMN2MAOBNPSR1KDM4E
SCHEMBL22135696 0.65 FABP6 (0.40) FABP6RAB9ASMN1; SMN2MAPK1THRB
SCHEMBL15525841 0.64 FABP6 (0.54) FABP6ALPLMAOBKDM4E
SCHEMBL19684652 0.63 PARP1 (0.36) PDE4DPDE4BPDE4APDE4CMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP FABP6 3697/4885PDE4D 3745/4885PDE4B 3019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.